Amazon trialling cancer vaccines

Latest News

Amazon trialling cancer vaccines

By Ross Henry Law

12/07/2022

Amazon is in the early phases of developing cancer vaccines in a collaboration with the Seattle-based Fred Hutchinson Cancer Centre.

The tech giant is collaborating on a study focussed on personalised vaccines for patients with melanoma or breast cancer that has metastasised to other parts of the body and has proven unresponsive to treatment.

The US-based study is currently preparing to enter phase one of an FDA-approved clinical trial for which it will recruit 20 test patients.

The study description states that the personalised neo-antigen peptide vaccine is a product which combines multiple patient-specific neo-antigens.

The vaccine may offer more focused and precise cancer treatments at a lower cost and may also prove to be a good alternative to chemotherapy, according to reporting by Business Insider.

The study began on June 9 and is set to be completed by November 2023.

National Technology has reached out to Amazon for further comment.

Bringing Teams to the table – Adding value by integrating Microsoft Teams with business applications

A decade ago, the idea of digital collaboration started and ended with sending documents over email. Some organisations would have portals for sharing content or simplistic IM apps, but the ways that we communicated online were still largely primitive.

Automating CX: How are businesses using AI to meet customer expectations?

Virtual agents are set to supplant the traditional chatbot and their use cases are evolving at pace, with many organisations deploying new AI technologies to meet rising customer demand for self-service and real-time interactions.